Talquetamab‐Induced Dysgeusia Successfully Treated With Photobiomodulation Therapy
- 17 July 2025
- journal article
- case report
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 236-239
Abstract
Multiple myeloma is a malignancy characterized by clonal proliferation of plasma cells in the bone marrow. The treatment of patients with relapsed or refractory multiple myeloma remains a challenge. Talquetamab is a recently approved drug, a first‐in‐class GPRC5D‐targeting T‐cell redirecting bispecific antibody, for treatment of patients with triple‐class exposed relapsed/refractory multiple myeloma. Patients who underwent drug therapy have experienced oral side effects such as xerostomia and dysgeusia. This report describes the case of a 61‐year old man with triple‐class exposed refractory multiple myeloma who developed talquetamab‐related dysgeusia that was successfully treated with photobiomodulation (PBM). The patient began to complain of loss of taste three days after the administration of talquetamab. PBM was performed every 48 h with 25 J/cm 2 per treatment field using the Therapy EC device (DMC; model number: #75153; red: 660 nm ±10 nm; infrared: 808 nm ±10 nm; fixed power of 100 mW ±20%; beam area of 0.04 cm 2 , and irradiance of 2.5 W/cm 2 ) during the talquetamab escalation phase. The application of laser was performed in 78 points distributed throughout the oral cavity. After 7 days/third session of PBM, the patient displayed a significant improvement in sensitivity to tastes, mainly salty and bitter. After 7 weeks of follow‐up, there was a slight reduction in sensibility to salty and no change in other tastes. The current clinical report demonstrated the potential effectiveness of a PBM protocol developed for the treatment of talquetamab‐related dysgeusia. The management of this oral side effect using PBM could prevent treatment interruption and improve the patients' quality of life.Keywords
Funding Information
- Universidade Estadual Paulista (1699/2023)
This publication has 7 references indexed in Scilit:
- Underexplored Areas of Photobiomodulation in Oral Oncology: An Expert AnalysisPhotobiomodulation, Photomedicine, and Laser Surgery, 2024
- Photobiomodulation minimizes taste changes during hematopoietic cell transplantation: A randomized clinical trialJournal of Biophotonics, 2024
- Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With TalquetamabClinical Lymphoma Myeloma and Leukemia, 2024
- Photobiomodulation in the Treatment of Dysgeusia in Patients with Long COVID: A Single-Blind, Randomized Controlled TrialPhotobiomodulation, Photomedicine, and Laser Surgery, 2024
- Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamabJournal of the American Academy of Dermatology, 2023
- Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022Frontiers in Oncology, 2022
- Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysgeusia and Oral Dryness as Side-Effects of Head and Neck Radiotherapy in a Cancer Patient: A Case ReportDentistry Journal, 2018